Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: A meta-analysis

Research output: Contribution to journalArticle

Abstract

Raloxifene, a selective estrogen receptor modulator, is indicated for the prevention of osteoporosis in postmenopausal women. However, its effect on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) is unclear. Therefore, we conducted a meta-analysis to evaluate the effect of raloxifene on these outcomes. To identify randomized controlled trials of raloxifene, a systematic search of PubMed, EMBASE, and Cochrane Collaboration databases was performed from the date of inception of these databases to October 2007. Search was limited to trials that were published in peer-reviewed English-language medical journals. Articles were included in the meta-analysis if they had reported on DVT, PE, or thromboembolic events. Nine trials, including 24,523 postmenopausal women, (median age 59.4 years, range 55 to 67 years; median follow-up 24 months, range 3 to 67 months) met inclusion criteria. Therapy with raloxifene was associated with a 62% increase in odds of either DVT or PE (odds ratio = 1.62; 95% confidence interval = 1.25 to 2.09; p-value <0.001). Similarly, raloxifene therapy was associated with 54% increase in odds of DVT (odds ratio = 1.54; 95% confidence interval = 1.13 to 2.11; p-value = 0.006) and 91% increase in odds of PE alone (odds ratio = 1.91;95% confidence interval = 1.05 to 3.47; p-value = 0.03). Raloxifene increases the risk of DVT and PE in postmenopausal women.

LanguageEnglish (US)
Pages338-342
Number of pages5
JournalThrombosis and Haemostasis
Volume99
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Venous Thromboembolism
Meta-Analysis
Pulmonary Embolism
Venous Thrombosis
Odds Ratio
Confidence Intervals
Therapeutics
Databases
Selective Estrogen Receptor Modulators
Postmenopausal Osteoporosis
PubMed
Raloxifene Hydrochloride
Language
Randomized Controlled Trials

Keywords

  • Deep venous thrombosis
  • Pulmonary embolism
  • Raloxifene
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Effect of raloxifene therapy on venous thromboembolism in postmenopausal women : A meta-analysis. / Adomaityte, Jurga; Farooq, Maria; Qayyum, Rehan.

In: Thrombosis and Haemostasis, Vol. 99, No. 2, 02.2008, p. 338-342.

Research output: Contribution to journalArticle

@article{b224af3eb1d047fe8e75ad5340bcd8c2,
title = "Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: A meta-analysis",
abstract = "Raloxifene, a selective estrogen receptor modulator, is indicated for the prevention of osteoporosis in postmenopausal women. However, its effect on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) is unclear. Therefore, we conducted a meta-analysis to evaluate the effect of raloxifene on these outcomes. To identify randomized controlled trials of raloxifene, a systematic search of PubMed, EMBASE, and Cochrane Collaboration databases was performed from the date of inception of these databases to October 2007. Search was limited to trials that were published in peer-reviewed English-language medical journals. Articles were included in the meta-analysis if they had reported on DVT, PE, or thromboembolic events. Nine trials, including 24,523 postmenopausal women, (median age 59.4 years, range 55 to 67 years; median follow-up 24 months, range 3 to 67 months) met inclusion criteria. Therapy with raloxifene was associated with a 62\{%} increase in odds of either DVT or PE (odds ratio = 1.62; 95\{%} confidence interval = 1.25 to 2.09; p-value <0.001). Similarly, raloxifene therapy was associated with 54\{%} increase in odds of DVT (odds ratio = 1.54; 95\{%} confidence interval = 1.13 to 2.11; p-value = 0.006) and 91\{%} increase in odds of PE alone (odds ratio = 1.91;95\{%} confidence interval = 1.05 to 3.47; p-value = 0.03). Raloxifene increases the risk of DVT and PE in postmenopausal women.",
keywords = "Deep venous thrombosis, Pulmonary embolism, Raloxifene, Venous thromboembolism",
author = "Jurga Adomaityte and Maria Farooq and Rehan Qayyum",
year = "2008",
month = "2",
doi = "10.1160/TH07-07-0468",
language = "English (US)",
volume = "99",
pages = "338--342",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - Effect of raloxifene therapy on venous thromboembolism in postmenopausal women

T2 - Thrombosis and Haemostasis

AU - Adomaityte,Jurga

AU - Farooq,Maria

AU - Qayyum,Rehan

PY - 2008/2

Y1 - 2008/2

N2 - Raloxifene, a selective estrogen receptor modulator, is indicated for the prevention of osteoporosis in postmenopausal women. However, its effect on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) is unclear. Therefore, we conducted a meta-analysis to evaluate the effect of raloxifene on these outcomes. To identify randomized controlled trials of raloxifene, a systematic search of PubMed, EMBASE, and Cochrane Collaboration databases was performed from the date of inception of these databases to October 2007. Search was limited to trials that were published in peer-reviewed English-language medical journals. Articles were included in the meta-analysis if they had reported on DVT, PE, or thromboembolic events. Nine trials, including 24,523 postmenopausal women, (median age 59.4 years, range 55 to 67 years; median follow-up 24 months, range 3 to 67 months) met inclusion criteria. Therapy with raloxifene was associated with a 62% increase in odds of either DVT or PE (odds ratio = 1.62; 95% confidence interval = 1.25 to 2.09; p-value <0.001). Similarly, raloxifene therapy was associated with 54% increase in odds of DVT (odds ratio = 1.54; 95% confidence interval = 1.13 to 2.11; p-value = 0.006) and 91% increase in odds of PE alone (odds ratio = 1.91;95% confidence interval = 1.05 to 3.47; p-value = 0.03). Raloxifene increases the risk of DVT and PE in postmenopausal women.

AB - Raloxifene, a selective estrogen receptor modulator, is indicated for the prevention of osteoporosis in postmenopausal women. However, its effect on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) is unclear. Therefore, we conducted a meta-analysis to evaluate the effect of raloxifene on these outcomes. To identify randomized controlled trials of raloxifene, a systematic search of PubMed, EMBASE, and Cochrane Collaboration databases was performed from the date of inception of these databases to October 2007. Search was limited to trials that were published in peer-reviewed English-language medical journals. Articles were included in the meta-analysis if they had reported on DVT, PE, or thromboembolic events. Nine trials, including 24,523 postmenopausal women, (median age 59.4 years, range 55 to 67 years; median follow-up 24 months, range 3 to 67 months) met inclusion criteria. Therapy with raloxifene was associated with a 62% increase in odds of either DVT or PE (odds ratio = 1.62; 95% confidence interval = 1.25 to 2.09; p-value <0.001). Similarly, raloxifene therapy was associated with 54% increase in odds of DVT (odds ratio = 1.54; 95% confidence interval = 1.13 to 2.11; p-value = 0.006) and 91% increase in odds of PE alone (odds ratio = 1.91;95% confidence interval = 1.05 to 3.47; p-value = 0.03). Raloxifene increases the risk of DVT and PE in postmenopausal women.

KW - Deep venous thrombosis

KW - Pulmonary embolism

KW - Raloxifene

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=38949102022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949102022&partnerID=8YFLogxK

U2 - 10.1160/TH07-07-0468

DO - 10.1160/TH07-07-0468

M3 - Article

VL - 99

SP - 338

EP - 342

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -